GleamWall
中文EN

EOLS Evolus, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1570562 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.1%
TTM net income YoY-16.5%
TTM EPS YoY-7.8%
Revenue 3-yr CAGR28.0%
Net income 3-yr CAGR—

Margins

Gross margin67.2%
Operating margin-15.5%
Net margin-22.3%
FCF margin-15.5%
EBITDA margin-14.0%

Returns

ROE-18,729.6%
ROA-26.8%
ROIC (approx.)-61.1%
Asset turnover1.20x

Leverage & solvency

Liabilities / assets108.2%
Debt / equity—
Current ratio2.27x
Interest coverage-2.06x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-8.9%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$297.18M$266.27M
Cost of revenue$100.07M$83.97M
Gross profit$197.11M$182.30M
R&D expense$9.58M$9.17M
SG&A expense$220.79M$198.03M
Operating income-$32.66M-$34.41M
Interest expense$19.69M$18.73M
Pretax income-$50.96M-$49.76M
Income tax$677,000$664,000
Net income-$51.64M-$50.42M
EBITDA-$25.16M-$29.11M
EPS (basic)-0.80-0.81
EPS (diluted)-0.80-0.81
Weighted avg. shares (diluted)64.47M62.02M
Balance sheet
Cash & equivalents$53.83M$86.95M
Receivables$54.70M$47.68M
Inventory$26.96M$12.16M
Current assets$142.92M$151.34M
PP&E, net$5.37M$3.22M
Goodwill$21.21M$21.21M
Intangibles$48.04M$48.75M
Total assets$225.87M$232.57M
Current liabilities$75.31M$62.96M
Long-term debt$146.10M$121.51M
Total debt$146.10M$121.51M
Total liabilities$248.97M$227.05M
Shareholders' equity-$23.11M$5.52M
Net debt$92.27M$34.55M
Shares outstanding65.01M63.50M
Cash flow statement
Operating cash flow-$42.27M-$18.00M
Capital expenditure$3.44M$1.47M
Free cash flow-$45.71M-$19.47M
Investing cash flow-$8.45M-$4.82M
Financing cash flow$17.34M$47.41M
Depreciation & amortization$7.51M$5.30M
Stock-based compensation$20.70M$22.25M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.